Table 2.
Association of adenomyosis and endometriosis with cancer: prognosis and evolution.
| Article | Number of Patients | Disease Free Survival (DSF) |
Overall Survival | Prognosis | Mean Age (Range) |
Muscle Invasion (≥½) |
Influence of Adenomyosis on Cancer |
|---|---|---|---|---|---|---|---|
| Akiyo Taneichi [28] 2014 (A) |
362 ▪ 121 (33.4%)—with adenomyosis; ▪ 241 (66.6%)—no adenomyosis; |
No difference | No difference | Similar | Adenomyosis 56 years (32–84) |
Significant p < 0.05 ▪ 19.5%—adenomyosis; ▪ 10.1%— non-adenomyosis; |
No significant influence on prognosis. |
| Hiroko Machida [10] 2017 (B) |
396 ▪ 46—EC-AIA (cancer arising from adenomyosis)—11.61%; ▪ 350—EC-A (cancer coexisting with adenomyosis)—88.39% |
No difference | OS decreased in EC-AIA p = 0.031 |
EC-AIA—poor prognosis | EC-AIA 58.9 years |
Significant p < 0.001 ▪ EC-AIA—51.6%; ▪ EC-A—19.4% |
Unclear |
| Marjolein Hermens [26] 2021 (C) |
129,872—enrolled ▪ 50,766 with endometriosis → 1827 developed endometrial cancer (3.59%); ▪ 85,051 with adenomyosis → 1408 developed endometrial cancer (1.65%) |
No difference | No difference | Similar Adenomyosis has a poor response at hormonal treatment |
Endometriosis 39 years (32–45) |
Not investigated | The heterogeneity of the study is overdue, but endometriosis seems to have a greater influence than adenomyosis. |
| Koji Matsuo [36] 2015 (D) |
1340 enrolled—all with endometrial cancer ▪ EC-AIA = 46 patients (3.43%); ▪ nonEC-AIA = 1294 patients (96.57%) |
Significant poorer in EC-AIA p = 0.014 |
Significantly decreased in EC-AIA p = 0.001 |
Poorer in EC-AIA | EC-AIA 58.9 years (58.9 ± 9.9) |
▪ EC-AIA—51.6%; ▪ nonEC-AIA—26.6%; Significant p = 0.002 |
With a lack of hormonal receptors in the cancer developed from adenomyosis ther was therefore a reduced hormonal response. |
EC-AIA—endometrial cancer arising from adenomyosis; nonEC-AIA—endometrial cancer developed independently from adenomyosis.